Patents by Inventor Colin Dingwall

Colin Dingwall has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Viral growth inhibition
    Patent number: 6153382
    Abstract: A synthetic molecule comprises at least one oligonucleotide comprising an RNA binding sequence or sequences corresponding to the site bound by the HIV protein rev and capable of binding ot rev within cells. The binding sequence or sequences, by binding with rev within cells, can act to cause inhibition of growth of any HIV present in the cells, and so has potential therapeutic use in treatment of patients infected with HIV. The invention also provides an assay for identifying that inhibit rev binding.
    Type: Grant
    Filed: September 15, 1997
    Date of Patent: November 28, 2000
    Assignee: Ribotargets, Ltd.
    Inventors: Jonathan Karn, Michael John Gait, Shaun Heaphy, Colin Dingwall
  • Viral (HIV) growth inhibition
    Patent number: 6114109
    Abstract: A synthetic molecule comprises at least one oligonucleotide, comprising and RNA binding sequence or sequences corresponding to the site bound by the HIV protein tat and capable of binding to tat within cells. The binding sequence or sequences, by binding tat within cells, can act to cause inhibition of growth of any HIV present in the cells, and so has potential therapeutic use in treatment of patients affected with HIV. The invention also provides an assay for identifying compounds that inhibit tat binding.
    Type: Grant
    Filed: May 22, 1998
    Date of Patent: September 5, 2000
    Assignee: RiboTargets, Ltd.
    Inventors: Jonathan Karn, Michael J. Gait, Shaun Heaphy, Colin Dingwall
  • RNA oligonucleotides that bind HIV tat protein
    Patent number: 5821046
    Abstract: A synthetic molecule comprising an RNA binding sequence or sequences corresponding to the site bound by the HIV protein tat and capable of binding to tat within cells. The binding sequence or sequences, by binding tat within cells, can act to cause inhibition of growth of any HIV present in the cells, and so has potential therapeutic use in treatment of patients affected with HIV. The invention also provides an assay for identifying compounds that inhibit tat binding.
    Type: Grant
    Filed: October 10, 1995
    Date of Patent: October 13, 1998
    Assignee: RiboTargets Holdings PLC
    Inventors: Jonathan Karn, Michael John Gait, Shaun Heaphy, Colin Dingwall
  • Oligonucleotide competitors for binding of HIV RRE to REV protein and assays for screening inhibitors of this binding
    Patent number: 5786145
    Abstract: A synthetic molecule comprises at least one oligonucleotide comprising an RNA binding sequence or sequences corresponding to the site bound by the HIV protein rev and capable of binding to rev within cells. The binding sequence or sequences, by binding rev within cells, can act to cause inhibition of growth of any HIV present in the cells, and so has potential therapeutic use in treatment of patients infected with HIV. The invention also provides an assay for identifying compounds that inhibit rev binding.
    Type: Grant
    Filed: October 10, 1995
    Date of Patent: July 28, 1998
    Assignee: Medical Research Council
    Inventors: Jonathan Karn, Michael John Gait, Shaun Heaphy, Colin Dingwall